The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
For individual iodine-131 ((131)I) treatment dosage calculations, most physicians use the 'standard dosage formula', which requires measurements of thyroid volume and thyroidal (131)I uptake. The effective half-life of (131)I (T(eff)) is then unjustifiably ignored. Evidence is presented that the 5/24h (131)I uptake ratio can be used as a surrogate parameter for T(eff), and that it is a determinant of the (131)I therapy outcome for patients with Graves' disease. A correction factor based on the thyroidal (131)I metabolism in individual patients could provide a means to increase the success rate of radioiodine treatment.
van Isselt
Johannes W
JW
Broekhuizen-de Gast
Henny S
HS
D003198:Computer Simulation; D006111:Graves Disease / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D017063:Outcome Assessment, Health Care / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals